Expert Opinion on Biological Therapy

Papers
(The TQCC of Expert Opinion on Biological Therapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli122
Biosimilars and access to biologic therapy in immune-mediated diseases63
Antibody drug conjugates for glioblastoma: current progress towards clinical use61
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions56
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol53
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease53
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?42
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males39
The endosomal-lysosomal system in ADC design and cancer therapy38
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases38
Aflibercept biosimilars – so near, yet so far33
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)30
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences27
Signaling new therapeutic opportunities: cytokines in prostate cancer27
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era27
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden27
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?25
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies25
Correction24
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway24
Long-acting delivery and therapies for neovascular age-related macular degeneration23
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors22
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma22
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas22
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study21
Correction21
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology20
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases20
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment20
Unmet needs in cervical cancer – can biological therapies plug the gap?20
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)20
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis19
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies19
Correction19
An evaluation of guselkumab for the treatment of ulcerative colitis19
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy18
Cell population data as predictive biomarkers for biologic therapy response in psoriasis18
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma18
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?18
Dynamics of biological markets with multiple biosimilar competitors in the United States18
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses18
Strategies for extending the half-life of biotherapeutics: successes and complications18
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors17
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer16
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies16
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives16
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease16
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities15
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?15
Where do we stand with radioimmunotherapy for acute myeloid leukemia?15
Management of proctitis in ulcerative colitis and the place of biological therapies15
The nail in psoriatic arthritis: new insights into prognosis and treatment15
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children15
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations14
Recent advances in delivering RNA-based therapeutics to mitochondria14
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward14
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis14
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region13
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-1913
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?13
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection13
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials13
Biological agents targeting interleukin-13 for atopic dermatitis13
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives13
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence13
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma13
Emerging peptide-based technology for biofilm control13
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease13
An evaluation of pozelimab for the treatment of CHAPLE disease13
Personalizing immunotherapy for renal cell carcinoma: how far have we come?13
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan12
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents12
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study12
Tarlatamab for small-cell lung cancer12
Belimumab patient profile in Spain: evolution during the last decade and future directions12
Tremelimumab for the treatment of hepatocellular carcinoma12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations12
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks12
Treating psoriasis in the elderly: biologics and small molecules12
Recent developments and future clinical prospects of polyclonal antibody therapies11
Non-traditional approaches for control of antibiotic resistance11
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects11
Antibody therapeutics for epithelial ovarian cancer11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis11
Clinical management and innovation in fracture non-union11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era11
Correction11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence11
Biosimilars in osteoporosis treatment: focus on denosumab11
X-linked myotubular myopathy: an untreated treatable disease10
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms10
Prostate cancer immunotherapy10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma10
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study10
Epcoritamab in B-cell malignancies: current status and prospects10
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials10
Sargramostim in acute radiation syndrome10
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer9
Hemophilia A gene therapy: current and next-generation approaches9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target9
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups9
Ravulizumab for the treatment of myasthenia gravis9
Biologics in rectal cancer9
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics9
Current status and future potential of CD123-based targeted therapies for acute leukemia9
Expression of Concern:9
Rilonacept for the treatment of recurrent pericarditis9
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells9
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective 9
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey8
The future of interleukin gene therapy in head and neck cancers8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa8
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk8
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease8
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz8
CAR T cells for solid tumors – developments to watch in 20238
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives8
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?8
The future of cellular therapy for the treatment of renal cell carcinoma8
0.073662996292114